Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma.

Journal: Nature communications
Published Date:

Abstract

Two tumor (Classical/Basal) and stroma (Inactive/active) subtypes of Pancreatic adenocarcinoma (PDAC) with prognostic and theragnostic implications have been described. These molecular subtypes were defined by RNAseq, a costly technique sensitive to sample quality and cellularity, not used in routine practice. To allow rapid PDAC molecular subtyping and study PDAC heterogeneity, we develop PACpAInt, a multi-step deep learning model. PACpAInt is trained on a multicentric cohort (n = 202) and validated on 4 independent cohorts including biopsies (surgical cohorts n = 148; 97; 126 / biopsy cohort n = 25), all with transcriptomic data (n = 598) to predict tumor tissue, tumor cells from stroma, and their transcriptomic molecular subtypes, either at the whole slide or tile level (112 µm squares). PACpAInt correctly predicts tumor subtypes at the whole slide level on surgical and biopsies specimens and independently predicts survival. PACpAInt highlights the presence of a minor aggressive Basal contingent that negatively impacts survival in 39% of RNA-defined classical cases. Tile-level analysis ( > 6 millions) redefines PDAC microheterogeneity showing codependencies in the distribution of tumor and stroma subtypes, and demonstrates that, in addition to the Classical and Basal tumors, there are Hybrid tumors that combine the latter subtypes, and Intermediate tumors that may represent a transition state during PDAC evolution.

Authors

  • Charlie Saillard
    Owkin Lab, Owkin, Inc., New York, NY, USA.
  • Flore Delecourt
    Université Paris Cité, Dpt of Pathology - FHU MOSAIC, Beaujon Hospital, INSERM U1149, Clichy, France.
  • Benoit Schmauch
    Owkin Lab, Owkin, Inc., New York, NY, USA.
  • Olivier Moindrot
    Owkin France, Medical Imaging Team, Paris, France.
  • Magali Svrcek
    Dpt of Pathology, Saint-Antoine Hospital - Sorbonne Universités, Paris, France.
  • Armelle Bardier-Dupas
    Dpt of Pathology, Pitié-Salpêtrière Hospital - Sorbonne Universités, Paris, France.
  • Jean Francois Emile
    Dpt of Pathology, Ambroise Paré Hospital - Université Saint Quentin en Yvelines, Paris, France.
  • Mira Ayadi
    Integragen, Genomic Services & Precision Medicine, Paris, France.
  • Vinciane Rebours
    Université Paris Cité, Dpt of Pancreatology - FHU MOSAIC, Beaujon Hospital, INSERM U1149, Clichy, France.
  • Louis de Mestier
    Université Paris Cité, Dpt of Pancreatology - FHU MOSAIC, Beaujon Hospital, INSERM U1149, Clichy, France.
  • Pascal Hammel
    Dpt of Medical oncology, Paul Brousse Hospital, Villejuif, France.
  • Cindy Neuzillet
    Medical oncology, Institut Curie, Paris, France.
  • Jean Baptiste Bachet
    Dpt of Gastroenterology, Pitié-Salpêtrière Hospital - Sorbonne Universités, Paris, France.
  • Juan Iovanna
    Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Institut Paoli-Calmettes, Aix Marseille Université, CNRS UMR 7258, Marseille, France.
  • Nelson Dusetti
    Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Institut Paoli-Calmettes, Aix Marseille Université, CNRS UMR 7258, Marseille, France.
  • Yuna Blum
    Institut Génétique et Développement de Rennes (IGDR), CNRS, Université de Rennes 1, UMR 6290, Rennes, France.
  • Magali Richard
    Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications Grenoble (TIMC-IMAG), CNRS, Université Grenoble-Alpes, UMR5525, Grenoble, France.
  • Yasmina Kermezli
    Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications Grenoble (TIMC-IMAG), CNRS, Université Grenoble-Alpes, UMR5525, Grenoble, France.
  • Valerie Paradis
    Université Paris Cité, Dpt of Pathology - FHU MOSAIC, Beaujon Hospital, INSERM U1149, Clichy, France.
  • Mikhail Zaslavskiy
    Owkin Lab, Owkin, Inc., New York, NY, USA.
  • Pierre Courtiol
    OWKIN Paris, France.
  • Aurelie Kamoun
    Programme cartes d'identite des tumeurs, Ligue nationale contre le cancer, Paris, France.
  • Remy Nicolle
    Université Paris Cité, FHU MOSAIC, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018, Paris, France.
  • Jérôme Cros
    Service d'anesthésie pédiatrique, Hôpital des Enfants, Limoges, France.